ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,058.00
      -0.12%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.67%
      Bitcoin
      66,844.80
      2.46%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Entera Bio Ltd (ENTX)

      7. Entera Bio Ltd (ENTX) News

      ENTX

      Entera Bio (ENTX)

      Entera Bio Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ENTX
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/15/20248:00AMGlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberNASDAQ:ENTXEntera Bio Ltd
      05/13/20247:00AMGlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
      05/10/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTXEntera Bio Ltd
      05/10/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      05/10/20244:10PMGlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
      04/08/20248:30AMGlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
      03/26/20248:30AMGlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
      03/20/20248:00AMGlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:25PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:12PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
      03/08/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:05PMGlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
      03/04/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      03/04/20248:30AMGlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
      02/15/20245:10PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
      02/15/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
      02/14/20246:05AMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
      02/02/20244:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      02/02/20244:17PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
      01/30/20248:30AMGlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
      01/16/20248:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/11/20246:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20246:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      01/02/20245:19PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ENTXEntera Bio Ltd
      12/27/20238:27AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
       Showing the most relevant articles for your search:NASDAQ:ENTX